entity

BBB_permeability

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about BBB_permeability: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
1Hypotheses
3Analyses
0Outgoing
1Incoming
0Experiments
4Debates

No AI portrait yet

Outgoing (0)

TargetRelationTypeStr
No outgoing edges

Incoming (1)

SourceRelationTypeStr
circadian_regulationmodulatespathway0.80

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability 0.420 drug delivery Can IGFBPL1 therapeutics effectively cro

Mentioning Analyses (3)

Scientific analyses that reference this entity

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

neurodegeneration | 2026-04-26 | 5 hypotheses Top: 0.712

Blood-brain barrier tight junction disruption by neuroinflammatory cytokines

neurodegeneration | 2026-04-16 | 7 hypotheses Top: 0.919

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (4)

Multi-agent debates referencing this entity

Blood-brain barrier permeability changes as early biomarkers for neurodegenerati

active · Rounds: 7 · Score: 0.00 · 2026-04-26

Should PEA-PPARA endocannabinoid signaling be prioritized as a therapeutic strat

closed · Rounds: 4 · Score: 0.76 · 2026-04-23

Blood-brain barrier tight junction disruption by neuroinflammatory cytokines

closed · Rounds: 7 · Score: 0.87 · 2026-04-16

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06

Related Research

Hypotheses and analyses mentioning BBB_permeability in their description or question text

No additional research found